Alumis Stock Has Soared 400%. Cormorant Bought Another $8 Million Last Quarter

Cormorant Asset Management increased its stake in Alumis by 313,645 shares ($7.84 million) in Q1 2026, bringing its position to 4.37% of assets. Alumis shares have surged 400% over the past year, driven by strong Phase 3 psoriasis trial data for its lead drug envudeucitinib. The company has $569.5 million in cash and plans to submit an NDA in Q4 2026, with pivotal lupus data expected in Q3.

05/17/2026, 2:13 PM • The Motley Fool

The Psoriasis Clinical Trial Pipeline Boom as 90+ Companies are in the Race for Better Treatments | DelveInsight

Over 90 pharmaceutical companies are actively developing more than 100 pipeline psoriasis drugs across various clinical stages. Key players including Takeda, Can-Fite BioPharma, Oruka Therapeutics, and others are advancing promising therapies with novel mechanisms of action such as TYK2 inhibitors and IL-23 inhibitors. Recent developments include positive Phase III results from Alumis and Takeda, and regulatory progress from multiple companies, indicating robust innovation in the psoriasis treatment landscape.

04/14/2026, 1:00 PM • GlobeNewswire

Alumis’ Envudeucitinib Delivers Early and Robust Improvements in Skin Clearance, Quality of Life and Psoriasis Symptoms in Two Phase 3 Trials, Underscoring Its Potential as a Leading Oral Therapy for Plaque Psoriasis

Alumis announced positive Phase 3 results for envudeucitinib, a TYK2 inhibitor for moderate-to-severe plaque psoriasis. The drug achieved PASI 90 responses in 68.0% and 62.1% of patients by Week 24, with PASI 100 complete clearance in 41.0% and 39.5%. Quality-of-life improvements and itch relief emerged early, with a favorable safety profile. The company plans to submit an NDA to the FDA in the second half of 2026.

03/28/2026, 1:30 PM • GlobeNewswire

Alumis Announces Pricing of Upsized Public Offering of Common Stock

Alumis Inc., a clinical-stage biopharmaceutical company, announced the pricing of an upsized underwritten public offering of 17.65 million shares at $17.00 per share, generating approximately $300 million in gross proceeds. The offering is expected to close on January 9, 2026, with underwriters granted a 30-day option to purchase an additional 2.65 million shares. Morgan Stanley, Leerink Partners, Cantor, and Wells Fargo Securities are serving as joint book-running managers.

01/07/2026, 10:52 PM • GlobeNewswire

Stock Market Today, Jan. 6: Alumis Shares Surge on Positive Phase 3 Psoriasis Data for Envudeucitinib

Alumis shares surged 94.53% following positive Phase 3 trial results for envudeucitinib, an oral TYK2 inhibitor for psoriasis that met primary and secondary endpoints. The company announced plans to raise $175 million in capital to support commercialization of the drug and its pipeline. The broader market rose modestly with the S&P 500 gaining 0.62% and Nasdaq up 0.65%.

01/06/2026, 5:12 PM • The Motley Fool

Alumis to Host Conference Call and Webcast to Report Phase 3 ONWARD Topline Data for Envudeucitinib in Moderate-to-Severe Plaque Psoriasis

Alumis Inc. announced it will report topline data from the Phase 3 ONWARD clinical program evaluating envudeucitinib for moderate-to-severe plaque psoriasis on January 6, 2026, at 8:00 a.m. ET. The company will host a conference call and webcast to discuss the results.

01/05/2026, 5:00 PM • GlobeNewswire

Thyroid Eye Disease Clinical Trial Pipeline Gains Momentum: 20+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight

Over 20 pharmaceutical companies are actively developing new treatments for Thyroid Eye Disease (TED), a serious autoimmune inflammatory condition affecting orbital tissues. The clinical trial pipeline is expanding with promising therapies targeting various mechanisms of the disease.

10/16/2025, 1:00 PM • GlobeNewswire

Alumis Misses Q2 Revenue as Costs Jump

Alumis reported mixed Q2 2025 results, with missed revenue expectations and high operating expenses due to the ACELYRIN merger. The company completed patient enrollment in key clinical trials for envudeucitinib and maintains sufficient funding through 2027.

08/13/2025, 4:28 PM • The Motley Fool